2020_CES_singlecell_ATAC - samples
Ontology highlight
ABSTRACT:
PROVIDER: EGAD00001005965 | EGA |
REPOSITORIES: EGA
Similar Datasets
Project description:ATAC-seq data for 26 CLL samples (7 controls, 19 tumor) of the CancerEpiSys-PRECiSe project.
| EGAD00001005967 | EGA
Project description:long RNA data for 27 CLL samples (8 controls, 19 tumor) of the CancerEpiSys-PRECiSe project.
| EGAD00001005968 | EGA
Project description:ChIPseq data for 31 CLL samples (12 controls, 19 tumor) of the CancerEpiSys-PRECiSe project; containing histone H3, histone modifications and transcription factor binding sites (CTCF, EBF1).
| EGAD00001005969 | EGA
Project description:WGBS data for 75 paired fastq, spread over 31 samples (4 healthy T-cell, 7 healthy B-cell, 20 B-cell CLL tumors) of the CancerEpiSys-PRECiSe project.
| EGAD00001005970 | EGA
Project description:Tagged-WGBS for 3 Naive B Cell samples of the CancerEpiSys-PRECiSe project.
| EGAD00001005966 | EGA
Project description:The transition of monoclonal B cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL) remains ill-defined at the epigenetic and transcriptional level. Here, we performed single cell RNA and ATAC sequencing of low-count (LC) and high-count (HC) MBL and CLL blood samples to track the continuum from physiologic B cells to CLL.
2026-03-31 | GSE295491 | GEO
Project description:The transition of monoclonal B cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL) remains ill-defined at the epigenetic and transcriptional level. Here, we performed single cell RNA and ATAC sequencing of low-count (LC) and high-count (HC) MBL and CLL blood samples to track the continuum from physiologic B cells to CLL.
2026-03-31 | GSE295490 | GEO
Project description:The transition of monoclonal B cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL) remains ill-defined at the epigenetic and transcriptional level. Here, we performed single cell RNA and ATAC sequencing of low-count (LC) and high-count (HC) MBL and CLL blood samples to track the continuum from physiologic B cells to CLL.
2026-03-31 | GSE295489 | GEO
Project description:Our project is based on the hypothesis that ibrutinib could interfere with chronic lymphocytic leukemia (CLL) microenvironment, modulating the immune response. The aim of the project is to understand if and how ibrutinib modifies the tumor microenvironment accessory cells in CLL, specifically nurse like cells (NLC).
2020-09-18 | GSE142292 | GEO
Project description:<p>BACKGROUND: Single ventricle congenital heart disease (SVCHD) is a severe form of cardiac malformation in which there is only one functional ventricle. The Fontan operation is the current standard of care for SVCHD. Almost all patients who have undergone the Fontan operation develop liver fibrosis at a young age, resulting in a condition known as Fontan-associated liver disease (FALD). The pathogenesis and mechanisms underlying FALD remain little understood, hindering development of effective therapies.</p><p>OBJECTIVES: We aimed to present a comprehensive multiomic analysis of human FALD, thereby revealing the fundamental biology and pathogenesis of FALD. </p><p>METHODS: We recently generated a single-cell transcriptomic and epigenomic atlas of human FALD using snRNA-ATAC-seq, which revealed profound metabolic reprogramming in FALD. Here we applied liquid chromatography-mass spectrometry (LC-MS) based untargeted metabolomics to unveil the metabolomic landscape of human FALD, using liver samples/biopsies from age and gender-matched healthy donors and FALD patients (n=12 per group). Extracted liver metabolites were analyzed by C18 high performance liquid chromatography (HPLC) and hydrophilic interaction chromatography (HILIC) followed by high resolution MS on Orbitrap. Statistical and bioinformatics analyses were performed to identify altered metabolites and metabolic pathways in FALD. These results were integrated with recently published snRNA-ATAC-seq and serum metabolomics datasets to present a comprehensive multiomic atlas of FALD. </p><p>RESULTS: We discovered profound metabolic abnormalities in livers of patients with early-stage FALD, particularly amino acid metabolism, peroxisomal fatty acid oxidation, cytochrome P450 system, glycolysis, TCA cycle, ketone body metabolism and bile acids metabolism. Integrated analyses with liver snRNA-ATAC-seq and serum metabolomics data unveiled the transcriptional mechanisms driving this metabolic reprogramming and the crosstalk between liver and the rest of the body. Comparison with human metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH) revealed dysregulated amino acid metabolism as a common metabolic abnormality. </p><p>CONCLUSIONS: Our comprehensive multiomic atlas of human FALD reveals the fundamental biology and pathogenesis mechanisms of FALD.</p>
2024-12-13 | MTBLS10782 | MetaboLights